CLINICAL_TRIALS trial_result · 2025-02-28

Clinical Trial Update: A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects [Phase 1]

Phase 1 study of AK119, an anti-CD73 antibody, evaluating safety in healthy subjects for COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Akesobio Australia Pty Ltd | Conditions: Coronavirus Disease 2019 (COVID-19) | Phase 1 | Status: COMPLETED